Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29-09-2020
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
PTAB upholds Biogen’s MS drug patent
23-03-2017
PictureDesignSwiss / Shutterstock.com
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera (dimethyl fumarate) should remain invalid because the matter had already been resolved by another court.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biogen, biotechnology, multiple-sclerosis, patent, US federal judge, generics, Mylan, DMF, Tecfidera, US District Court for the District of Delaware
